Arsenal-backed CellCarta expands portfolio with new purchase

CellCarta has acquired the commercial rights to the antibody panels and assays from Precision Assays, a Seattle, Washington-based targeted proteomics testing solutions provider.

To read this article, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

New to PE Hub?

Register now to read this article and more for free.